Lipid management in human immunodeficiency virus

Cardiol Clin. 2015 May;33(2):277-98. doi: 10.1016/j.ccl.2015.01.003.

Abstract

The development and use of antiretroviral medications to treat patients infected with human immunodeficiency virus (HIV) has dramatically changed the course of this disease from one that was fatal to a chronic and more manageable condition. Recommendations and guidelines for the general population are presented in this review with suggestions as to how they may be applied to this patient population. Issues for which there is little or no information available are noted to highlight the many gaps in our knowledge regarding diagnosis and management of dyslipidemia for patients living with HIV.

Keywords: Antiretroviral therapy; Cardiovascular risk factors; Dyslipidemia; HIV; Infectious diseases.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Anti-Retroviral Agents / therapeutic use*
  • Disease Management*
  • Dyslipidemias* / blood
  • Dyslipidemias* / complications
  • Dyslipidemias* / therapy
  • HIV Infections* / blood
  • HIV Infections* / complications
  • HIV Infections* / therapy
  • HIV*
  • Humans
  • Hypolipidemic Agents / therapeutic use*
  • Lipids / blood*
  • Risk Factors

Substances

  • Anti-Retroviral Agents
  • Hypolipidemic Agents
  • Lipids